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Purpose: In this randomized, double-blind study, we
investigated the analgesic efficacy and side effects of con-
tinuous constant-dose infusions of remifentanil after total
abdominal hysterectomy and compared it to fentanyl.
Materials and Methods: Fifty-six adult female patients
scheduled for elective total abdominal hysterectomy were
enrolled in this study. Patients were randomly assigned to
two groups according to fentanyl (group F, n = 28) or
remifentanil (group R, n = 28) for postoperative analgesia.
Patients in group F were given fentanyl intravenously with
an infusion rate of fentanyl 0.5 g/kg/hr; group R was givenμ
remifentanil with an infusion rate of remifentanil 0.05 g/kg/μ
min for 2 days. Pain intensity at rest, occurrence of post-
operative nausea and vomiting (PONV), dizziness, pruritus,
and respiratory depression were assessed 1 hr after arrival at
the post-anesthesia care unit, at 6; 12; 24; and 48 hr post-
operation and 6 hr post-infusion of the study drug. Pain was
evaluated by using visual analogue scale (VAS; 0 - 10). The
time that patients first requested analgesics was recorded as
well as additional analgesics and antiemetics. Results: There
were no significant differences in VAS, time to first posto-
perative analgesics, and additional analgesics between the 2
groups. The incidences and severities of PONV and opioid
related side effects were not different between the groups;
however, there were 3 episodes (10.7%) of serious respiratory
depression in group R. Conclusion: Continuous infusion
technique of remifentanil did not reveal any benefits
compared to fentanyl. Furthermore, it is not safe for
postoperative analgesia in the general ward.
Key Words: Postoperative nausea and vomiting, postoperative
pain control, remifentanil, respiratory depression
INTRODUCTION
Postoperative pain is one of the most important
problems that confront surgical patients because it
affects the cardiovascular, respiratory, and endo-
crine systems. Proper perioperative analgesia
management may reduce the occurrence of
serious postoperative complications.1
Continuous infusion of analgesics has been a
method used to manage postoperative pain. This
technique minimizes the fluctuation of analgesic
medication in the blood, which provides more
efficient pain management than the intermittent
injection of analgesics.
Remifentanil, agonist opioid, has a very fastμ
onset and an ultra-short duration of action
because of rapid hydrolysis of the methyl ester
linkage by nonspecific blood and tissue
esterases.
2-4
The time required for a 50% reduction
in blood concentration after the discontinuation of
an infusion that attains a steady state (context-
sensitive half-time) is about 3 minutes, and it does
not increase with the duration of infusion. These
unique pharmacokinetic properties of remifentanil
should confer ease of titration to changing
intraoperative conditions and make it an ideal
agent for postoperative analgesia. A previous
study observed that remifentanil with an infusion
rate of 0.05 - 0.15 g/kg/min provides goodμ
postoperative analgesia for major surgical
procedures,
5
and a recent study showed that
remifentanil reduces the incidence of side effects,
especially postoperative nausea and vomiting
(PONV), compared to fentanyl.
6
However, intravenous administration of remi-
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fentanil has the potential to induce opioid-in-
duced side effects, such as respiratory depression,
and there are few studies that investigate the
efficacy and side effects of remifentanil for post-
operative pain control after abdominal surgery.
This randomized, double-blinded study was
conducted for 2 purposes; to compare the an-
algesic efficacy of continuous constant-dose infu-
sions of remifentanil after total abdominal
hysterectomy (TAH) compared to fentanyl and
assess the side effects of opioids infusions,
especially in PONV.
MATERIALS AND METHODS
The Consolidated Standards of Reporting Trials
(CONSORT) recommendations for reporting ran-
domized, controlled clinical trials were followed.
After obtaining approval of the Institutional
Review Board from Yonsei University Medical
Center and written informed consent from
patients, 56 ASA physical status I adult female
patients scheduled for elective TAH were enrolled
in this study. Patients under 18 or over 65 years
of age; with neurological, psychiatric, endo-
crinologic, renal or hepatic disorders; allergy to
opioids; or taking analgesic, antiemetic or psycho-
active drugs were excluded. The principles of pain
control device and visual analogue scale (VAS) for
pain assessment were explained to patients on the
day of the pre-anesthetic visit.
Premedication was not prescribed. All patients
were monitored by electrocardiography, noninva-
sive blood pressure, and pulse oximetry when
they arrived at the operating theater. The anesthetic
techniques were standardized. Anesthesia was
induced with 1.5 mg/kg of propofol and 1 g/kgμ
of remifentanil. For neuromuscular blockade, 0.6
mg/kg of rocuronium was given by IV. After
tracheal intubation, the lungs were ventilated with
50% air in oxygen, and anesthesia was maintained
with 1 - 2% sevoflurane and 0.1 g/kg/min ofμ
remifentanil. No other sedative, analgesic, or
antiemetic drug was administered.
Patients were randomly allocated to 2 groups to
receive either fentanyl (group F, n = 28) or remi-
fentanil (group R, n = 28) for their postoperative
analgesia. Randomization was achieved by using
sequentially numbered, opaque-sealed envelopes
containing computer-generated random alloca-
tions in a ratio of 1 : 1 in balanced blocks of 8.
Patients in group F were given fentanyl with an
infusion rate of 0.5 g/kg/hr IV and group Rμ
patients were given remifentanil with an infusion
rate of 0.05 g/kg/min IV for 2 days, which isμ
minimum amount of known efficacy of remifentanil
in major surgical procedures.5 The study solution
was prepared by an anesthesiologist who was not
involved in the trial. Approximately 30 min before
the anticipated end of surgery, an infusion pump
(Infusor SV2, Boxter Health care Co., Deerfield, IL,
USA) was attached to a continuously infusing
intravenous catheter. At the end of surgery,
neuromuscular block was reversed with 0.03 mg/
kg of neostigmine and 0.004 mg/kg of glycopyrro-
late by IV. After adequate spontaneous respira-
tion, the trachea was extubated.
The anesthesiologist, who did not know the
study protocol, assessed patients in the post-
anesthesia care unit (PACU) and subsequently in
the general ward. Each patient was assessed 1 hr
after arrival at PACU, at 6; 12; 24; and 48 hr
post-operation and 6 hr post-infusion of the study
drug by an investigator blinded to the patient
group. Respiratory depression was assessed in
postoperative periods. A respiratory rate 10
was defined as respiratory depression. Pain
intensity at rest, occurrences and severities of
PONV, dizziness, and pruritus were also assessed
(0 = none, 1 = mild, 2 = moderate and required
treatment, 3 = severe and refractory to the treat-
ment). Pain was evaluated by using VAS at
resting state with 10 meaning maximum pain and
0 meaning no pain. Rescue analgesia was pro-
vided with 30 mg of ketorolac by IV when pain
intensity on VAS was 5, the daily maximum
dose of which was 90 mg. The time when patients
first requested analgesics and additional an-
algesics was recorded.
An additional analysis of the severity of PONV
was performed,7 which was categorized into 4
degrees using the following standardized scoring
algorithm that has been used in similar trials:8,9
“No PONV”: Absence of any emetic episodes
and nausea.
“Mild PONV”: 1) Patients had only mild
nausea. 2) One emetic episode or short lasting
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nausea of any severity (< 10 min) occurred but
was triggered by an exogenous stimulus, such as
drinking, eating, or postoperative movement.
After the stimulus, nausea diminished and patients
felt well again throughout the entire study period.
No antiemetics drug was necessary.
“Moderate PONV”: 1) Patients had 1 - 2 emetic
episodes or moderate to severe nausea without
exogenous stimulus. 2) Patients required antie-
metics therapy once.
“Severe PONV”: Patients had more than 2
emetic episodes or were nauseated more than two
times (moderate or severe). The administration of
at least more than 1 antiemetic was necessary.
Four mg of ondansetron was administered by
IV when patients requested. The additional doses
of antiemetics were recorded.
Power calculation indicated that 30 patients per
group would be required to detect a difference of
50% in case of PONV, which was 40% in the
previous study5 with a power of 90%.
All data were expressed as mean ± standard
deviation or number (n). Comparisons of demo-
graphic data between the groups were made
using Student t-test. Comparisons of VAS, side
effects of opioids, additional analgesics, and use of
antiemetics were made using Mann-Whitney U
test. A p value < 0.05 was considered statistically
significant. SPSSTM version 12.5 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis.
RESULTS
Fifty-six patients were enrolled in this study.
Demographic characteristics of patients and the
duration of surgery were similar between the 2
groups (Table 1). Four patients in group R left the
study because of 1 case of severe PONV and 3
cases of serious respiratory depression.
There were no significant differences in VAS,
time to first postoperative analgesics, and addi-
tional analgesics between the groups (Table 2).
Although 1 patient experienced severe PONV
and infusion of the study solution was stopped,
the incidence and severity of PONV were not
different between the groups (Table 3). Further-
more, there were no statistical differences in the
antiemetics used between the groups. The
incidence and severity of dizziness were not
different between the groups (Table 3). No
patients in either group complained of pruritus.
However, there were 3 episodes (10.7%) of serious
respiratory depression in group R, but none in
group F, therefore, the current study inevitably
came to an end.
The first patient was a 27 years old woman with
a body weight of 48 kg. On the first postoperative
day (POD 1), an antibiotic cefotiam diluted by 4
mL of distilled water was injected into the patient
(skin test was negative). The patient was found
cyanotic and experienced loss of consciousness
(LOC). Cardiopulmonary resuscitation (CPR)
started immediately and the patient regained
consciousness after about 10 min. There was no
abnormality found on the ECG, chest X-ray,
complete blood count, serum electrolytes, arterial
blood gas analysis, and cardiac enzyme levels.
The patient was discharged on POD 7 without
problems. The second patient was a 43 years old
woman with a body weight of 61 kg. On POD 2,
a new fluid bag was connected to the IV tubing,
and several drops of fluid ran into the tubing
while changing the fluid bag. The patient became
Table 1. Patient Demographic Data and Intraoperative Characteristics
Group F (n = 28) Group R (n = 28)
Age (yrs) 45.6 ± 9.7 41.5 ± 10.8
Height (cm) 159.2 ± 5.3 159.1 ± 5.1
Weight (kg) 59.3 ± 7.6 57.1 ± 6.4
Duration of surgery (min) 99.6 ± 56.7 110.5 ± 45.6
Group F, fentanyl 0.5 µg/kg/hr IV; Group R, remifentanil 0.05 µg/kg/min IV for postoperative pain control.
There were no significant differences between the groups.
Values are mean ± SD.
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apneic, CPR was initiated, and the patient was
intubated. Soon after, she began breathing
spontaneously and was extubated. On neurologic
examination and brain MRI, no abnormalities
were found. The patient was discharged on POD
8. The third patient was a 46 years old woman
with a body weight of 52 kg. She received an IV
dose of cimetidine in the same intravenous line
followed by 2 mL of flush solution. She imme-
diately became cyanotic and apneic. We initiated
CPR and she awoke shortly afterward. Sub-
sequent examination revealed normal results, and
the patient recovered without incident. In patients
2 and 3, we suspected malfunction of the infusor.
After collecting Infusor SV2, we ran it for 24 hr
to look for any malfunctions, but we did not find
any abnormalities.
DISCUSSION
In the present study, the continuous infusion of
remifentanil provided the same quality of an-
algesia after TAH as fentanyl in these clinical
Table 2. Postoperative VAS and Additional Analgesics
Group F Group R
PACU n 28 28
Time to first postoperative analgesics (min) 30.0 ± 5.6 40.0 ± 6.7
VAS 7.0 ± 0.5 6.0 ± 0.5
Additional ketorolac (mg) 45 ± 6 30 ± 9
Number of patients needed NSAIDs (%) 50% 46%
Postop 6 hr n 28 28
VAS 4.0 ± 0.5 4.0 ± 0.5
Additional ketorolac (mg) 30 ± 3 15 ± 3
Number of patients needed NSAIDs (%) 46% 46%
Postop 12 hr n 28 26
VAS 3.0 ± 0.5 3.0 ± 0.4
Additional ketorolac (mg) 0 ± 3 0 ± 3
Number of patients needed NSAIDs (%) 30% 27%
Postop 24 hr n 28 25
VAS 2.0 ± 0.4 1.0 ± 0.4
Additional ketorolac (mg) 0 ± 3 0
Number of patients needed NSAIDs (%) 7% 0%
Postop 48 hr n 28 24
VAS 2.0 ± 0.2 1.0 ± 0.3
Additional ketorolac (mg) 0 0 ± 3
Number of patients needed NSAIDs (%) 0% 4%
Postinfusion 6 hr n 28 24
VAS 2.0 ± 0.3 1.0 ± 0.3
Additional ketorolac (mg) 0 0 ± 3
Number of patients needed NSAIDs (%) 0% 4%
Group F, fentanyl 0.5 µg/kg/hr IV; Group R, remifentanil 0.05 µg/kg/min IV for postoperative pain control.
PACU, postoperative anesthesia care unit; Postop, postoperative; Postinfusion 6 hr, 6 hr after the end of infusion of the study
drug; n, number of analyzed patients; Time to the first analgesics was defined from arrival at PACU; Additional ketorolac, the
dosage of ketorolac required during the time intervals.
Values are median ± SE or number of patients.
There were no significant differences between the groups.
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settings. There were no differences in VAS, in-
cidences and severities of PONV, dizziness,
additional analgesics, and antiemetics between the
2 groups. However, there were 3 episodes of
serious respiratory depression in group R.
An ultra-short acting opioid such as remifen-
tanil is preferred to a long-acting opioid such as
morphine because remifentanil does not have any
significant adverse effects on the cardiovascular
system and does not accumulate in the body
compared to other opioids.
4
In addition, intrao-
perative remifentanil also produces less PONV
than intraoperative fentanyl.6 These features of
remifentanil could make it an ideal agent for
postoperative analgesia. In this study, we
employed a continuous background infusion of
remifentanil since the pharmacokinetic profile of
remifentanil makes it suitable for the continuous
infusion.
There are some articles that advocate favorable
results of remifentanil infusion for postoperative
pain,
5,10-14
especially in critical patients,
10,11,14
but
the authors stopped the current study when 3
patients from the group R had serious respiratory
depression.
The amount of remifentanil that we chose for
this study was the minimum amount of known
efficacy of remifentanil in major surgical pro-
cedures and was comparable to previous studies
as well as clinical experience.5,10-14 Although there
have been no studies so far about equipotent
doses of fentanyl and remifentanil for postoperative
pain control, fentanyl in this study was infused at
the recommended basal infusion rate15 and
remifentanil was also infused at the basal infusion
rate known to be effective for postoperative pain
Table 3. Side Effects of Opioids and Use of Antiemetics
Group F Group R
PACU PONV 1.0 ± 0.2 0.0 ± 0.2
Dizziness 0.0 ± 0.2 0.0 ± 0.1
Antiemetics (ampule) 0.0 ± 0.1 0.0 ± 0.1
Postop 6 hr PONV 1.0 ± 0.1 1.0 ± 0.1
Dizziness 0.0 ± 0.1 0.0 ± 0.1
Antiemetics (ampule) 0.0 ± 0.1 0.0 ± 0.1
Postop 12 hr PONV 0.0 ± 0.1 0.0 ± 0.1
Dizziness 0.0 ± 0.1 0.0 ± 0.1
Antiemetics (ampule) 0 0.0 ± 0.1
Postop 24 hr PONV 0.0 ± 0.1 0.0 ± 0.1
Dizziness 0.0 ± 0.1 0
Antiemetics (ampule) 0 0
Postop 48 hr PONV 0.0 ± 0.1 0.0 ± 0.1
Dizziness 0.0 ± 0.1 0
Antiemetics (ampule) 0 0
Postinfusion 6 hr PONV 0.0 ± 0.1 0.0 ± 0.1
Dizziness 0.0 ± 0.1 0
Antiemetics (ampule) 0 0
Group F, fentanyl 0.5 µg/kg/hr IV; Group R, remifentanil 0.05 µg/kg/min IV for postoperative pain control.
The severity of side effects related to opioid was rated as: 0 = none, 1 = mild, 2 = moderate, 3 = severe and refractory
to the treatment.
PACU, postoperative anesthesia care unit; Postop, postoperative; Postinfusion 6 hr, 6 hr after the end of infusion of
the study drug; Antiemetics; the number of required antiemetics during the time intervals.
Values are median ± SE.
There were no significant differences between the groups.
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control.5,11,12,14 Patient-controlled analgesia tech-
nique is more effective in cases of IV pain control,
but our study used only basal infusion for fear
that bolus doses of remifentanil might cause
respiratory depression.5,16-19
It might have been appropriate to measure drug
concentration during the study period in an effort
to compare whether our infusions were indeed
equipotent. However, our aim was to compare
these agents in a study that was clinically relevant
and not as a direct comparison of their respective
pharmacokinetic properties. Since there were no
differences in the amount of additional analgesics
given and the severity of pain under basal
infusion of fentanyl and remifentanil in this study,
it is assumed that the basal infusion rates used in
this study are comparable.
Bowdle et al. evaluated the use of an infusion
of remifentanil to provide postoperative analgesia
during PACU stay.5 One hundred fifty-seven
patients from 7 medical centers were enrolled,
and apnea occurred in 11 patients (7%). Of the 11
apneic patients, 9 had received boluses of remi-
fentanil prior to the onset of apnea. They reported
1 case of respiratory depression with a possible
explanation: The remifentanil infusion was
piggybacked into a standard IV infusion line. The
“dead space” of the main IV tubing between the
port where the remifentanil was inserted into the
main IV tubing and the patient’s vein could have
varied from approximately 1 to 5 mL. Thus,
changes in the rate of flow in the main IV tubing
could have a substantial impact on the moment-
to-moment delivery of remifentanil. If the flow in
the main IV tubing were suddenly increased
substantially, the remifentanil contained in the
dead space of the IV tubing would suddenly be
flushed into the patient. Such a bolus could easily
produce respiratory depression, including apnea.5
In our cases, these events occurred right after side
shooting of a medication or fluid flush of the main
IV tubing. A small amount of remifentanil
accumulated in the IV tubing can cause serious
respiratory depression during postoperative pain
control even in young and ASA I patients,
especially in a general ward where continuous
vital monitoring is not a common practice.
In the current study, an IV infusor was con-
nected via a 3-way stopcock that was attached to
a 70-cm-long, 5 mL volume IV extension line. The
exact amount of remifentanil delivered to the
patient while mishaps with IV tubing cannot be
measured. Nevertheless, we can estimate the
amount of remifentanil introduced into the IV
main tubing. During the post-op period, the main
fluid is usually infused at a rate of 120 mL/hr. In
patient 1, 4 mL of diluted antibiotics was injected;
therefore, about 4.6 g of remifentanil could beμ
injected. In patient 3, when 2 mL of fluid was
flushed to the main IV tubing, about 2.5 g ofμ
remifentanil could be injected. However, if the
main fluid was injected at a slower rate, more
study solution could have built up in the IV
tubing.
Egan et al. demonstrated that bolus injection of
remifentanil would be potentially safe and effec-
tive in clinical situation.20 However, some younger
subjects also experienced respiratory depression at
a relatively low dose of remifentanil and episodes
of apnea occurred in 4 subjects. In addition, after
25 g of remifentanil injections, respiratory depresμ -
sion developed in both younger and older
subjects.
The primary side effect of concern in association
with remifentanil in spontaneously ventilating
patients is respiratory depression and apnea. Rapid
onset opioids such as remifentanil are especially
troublesome in this regard because the carbon
dioxide ventilation-response curve (i.e. the rela-
tionship between minute volume and PaCO2) is
altered before the patient's PaCO2 rises suffici-
ently to sustain ventilatory drive.
17,18
Even though there are reports of successful
remifentanil injection via bolus or IV PCA
(patient-controlled analgesia), it can cause signifi-
cant complications. While using remifentanil
infusion for postoperative pain control, an ex-
tremely small dose of remifentanil can cause
serious respiratory depression. Careful monitoring
of respiratory function and skills in the recogni-
tion and treatment of inadequate respiration
would be obligatory in a clinical setting when
using remifentanil.
The present results show that a background
infusion technique using remifentanil provides
equal pain relief as measured by VAS and cannot
reduce the incidence of PONV compared to
fentanyl administration. However, serious respira-
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tory depression was observed during continuous
infusion of remifentanil but not fentanyl. Our
study indicates that IV continuous infusion
technique using remifentanil for postoperative
analgesia would cause serious respiratory depres-
sion in spontaneously ventilating patients.
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